STERIS’ (TSE:STE – Get Rating) – Stifel Firstegy dropped their FY2022 earnings per share (EPS) estimates for STERIS’ in a research report issued to clients and investors on Thursday, September 15th. Stifel Firstegy analyst C. Pereira now expects that the company will post earnings per share of $1.10 for the year, down from their previous estimate of $1.11. Stifel Firstegy also issued estimates for STERIS’’s FY2023 earnings at $1.42 EPS.
STERIS’ Price Performance
STERIS’ (TSE:STE – Get Rating) last posted its earnings results on Wednesday, August 10th. The company reported C$0.54 EPS for the quarter, topping the consensus estimate of C$0.20 by C$0.34. The business had revenue of C$273.00 million for the quarter, compared to analyst estimates of C$252.87 million.
STERIS’s MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe by providing innovative healthcare and life science product and service solutions around the globe.
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
Receive News & Ratings for STERIS’ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS’ and related companies with MarketBeat.com's FREE daily email newsletter.